What happened in optometry this week: September 9
FDA accepts Palatin's PL9643 Phase 3 trials for dry eye disease; optometrists' role in geographic atrophy treatment evolves; The Vision Council reports decline in practice performance; theories on autism and eye tracking explored; NovaSight's CureSight device shows efficacy in amblyopia treatment.
Reference News
What happened in optometry this week: September 9
FDA accepts Palatin's PL9643 Phase 3 trials for dry eye disease; optometrists' role in geographic atrophy treatment evolves; The Vision Council reports decline in practice performance; theories on autism and eye tracking explored; NovaSight's CureSight device shows efficacy in amblyopia treatment.